Warning: The NCBI web site requires JavaScript to function. more...
Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.
Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT.
Arthritis Res Ther. 2009;11(4):R131. Epub 2009 Aug 28.
Related citations
Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M.
Arthritis Res Ther. 2009;11(4):R123. Epub 2009 Aug 17.
Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.
Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JC.
Rheumatology (Oxford). 2007 Jan;46(1):29-36. Epub 2006 May 30.
Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.
Arthritis Rheum. 2007 Dec;56(12):3909-18.
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC.
Arthritis Rheum. 2006 Feb;54(2):613-20.
Rituximab treatment in rheumatoid arthritis: how does it work?
Boumans MJ, Tak PP.
Arthritis Res Ther. 2009;11(6):134. Epub 2009 Nov 24.
Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP.
Arthritis Rheum. 2006 Aug;54(8):2377-86.
Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.
Szodoray P, Alex P, Dandapani V, Nakken B, Pesina J, Kim X, Wallis GL, Wilson PC, Jonsson R, Centola M.
Scand J Immunol. 2004 Jul-Aug;60(1-2):209-18.
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC.
Arthritis Rheum. 2006 Mar;54(3):723-32.
Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.
Julià A, Barceló M, Erra A, Palacio C, Marsal S.
Pharmacogenomics. 2009 Oct;10(10):1697-708.
Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A.
Arthritis Rheum. 2010 Jan;62(1):64-74.
Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M.
Arthritis Rheum. 2010 Jan;62(1):75-81.
Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
Roll P, Dörner T, Tony HP.
Arthritis Rheum. 2008 Jun;58(6):1566-75.
Bone marrow CD34+ progenitor cells from rheumatoid arthritis patients support spontaneous transformation of peripheral blood B cells from healthy individuals.
Hirohata S, Yanagida T, Nakamura H, Yoshino S, Tomita T, Ochi T.
Rheumatol Int. 2000;19(4):153-9.
Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis.
Möller B, Aeberli D, Eggli S, Fuhrer M, Vajtai I, Vögelin E, Ziswiler HR, Dahinden CA, Villiger PM.
Arthritis Res Ther. 2009;11(3):R62. Epub 2009 May 6.
CD19: a promising B cell target for rheumatoid arthritis.
Tedder TF.
Nat Rev Rheumatol. 2009 Oct;5(10):572-7. Review.
Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab.
Palanichamy A, Roll P, Theiss R, Dörner T, Tony HP.
Arthritis Rheum. 2008 Dec;58(12):3665-74.
Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y.
Arthritis Rheum. 2011 Dec;63(12):3692-701. doi: 10.1002/art.30599.
Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, Treter S, Harper D, Kitamura H, Vitetta ES, Abraham S, Awwad M, White-Scharf ME, Sachs DH, Thall A, Cooper DK.
Xenotransplantation. 2001 Aug;8(3):157-71.
Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.
Vital EM, Dass S, Rawstron AC, Buch MH, Goëb V, Henshaw K, Ponchel F, Emery P.
Arthritis Rheum. 2010 May;62(5):1273-9.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on